Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
28216224
DOI
10.1016/j.bbapap.2017.02.012
PII: S1570-9639(17)30036-5
Knihovny.cz E-zdroje
- Klíčová slova
- Breast cancer, Estrogen receptor, Lymph node, Selected reaction monitoring, Tumor grade, mTRAQ,
- MeSH
- dospělí MeSH
- faktory depolymerizující aktin biosyntéza genetika MeSH
- invazivní růst nádoru genetika patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfatické metastázy MeSH
- lymfatické uzliny metabolismus patologie MeSH
- molekuly buněčné adheze biosyntéza genetika MeSH
- nádorové biomarkery biosyntéza genetika MeSH
- nádorové proteiny biosyntéza genetika MeSH
- nádory prsu genetika patologie MeSH
- přežití bez známek nemoci MeSH
- prognóza MeSH
- proteiny vázající RNA biosyntéza genetika MeSH
- proteomika MeSH
- receptory pro estrogeny genetika MeSH
- regulace genové exprese u nádorů MeSH
- senioři MeSH
- stathmin biosyntéza genetika MeSH
- thrombospondiny biosyntéza genetika MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- faktory depolymerizující aktin MeSH
- molekuly buněčné adheze MeSH
- nádorové biomarkery MeSH
- nádorové proteiny MeSH
- POSTN protein, human MeSH Prohlížeč
- proteiny vázající RNA MeSH
- receptory pro estrogeny MeSH
- SERBP1 protein, human MeSH Prohlížeč
- stathmin MeSH
- STMN1 protein, human MeSH Prohlížeč
- thrombospondin 2 MeSH Prohlížeč
- thrombospondiny MeSH
Breast cancer is the most common and molecularly relatively well characterized malignant disease in women, however, its progression to metastatic cancer remains lethal for 78% of patients 5years after diagnosis. Novel markers could identify the high risk patients and their verification using quantitative methods is essential to overcome genetic, inter-tumor and intra-tumor variability and translate novel findings into cancer diagnosis and treatment. We recently identified 13 proteins associated with estrogen receptor, tumor grade and lymph node status, the key factors of breast cancer aggressiveness, using untargeted proteomics. Here we verified these findings in the same set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM), transcriptomics and immunohistochemistry and validated in 5 independent sets of 715 patients using transcriptomics. We confirmed: (i) positive association of anterior gradient protein 2 homolog (AGR2) and periostin (POSTN) and negative association of annexin A1 (ANXA1) with estrogen receptor status; (ii) positive association of stathmin (STMN1), cofilin-1 (COF1), plasminogen activator inhibitor 1 RNA-binding protein (PAIRBP1) and negative associations of thrombospondin-2 (TSP2) and POSTN levels with tumor grade; and (iii) positive association of POSTN, alpha-actinin-4 (ACTN4) and STMN1 with lymph node status. This study highlights a panel of gene products that can contribute to breast cancer aggressiveness and metastasis, the understanding of which is important for development of more precise breast cancer treatment.
Citace poskytuje Crossref.org
Breast Cancer Classification Based on Proteotypes Obtained by SWATH Mass Spectrometry
